|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.62 CAD | +9.26% |
|
+18.39% | +59.34% |
Company Valuation: Satellos Bioscience Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6.794 | 36.73 | 95.65 | 89.3 | 169.6 | - | - |
| Change | - | 440.53% | 160.46% | -6.65% | 89.88% | - | - |
| Enterprise Value (EV) 1 | 6.794 | 36.73 | 46.68 | 89.3 | 75.9 | 58.2 | -14.25 |
| Change | - | 440.53% | 27.11% | 91.29% | -15% | -23.32% | -124.48% |
| P/E | - | - | -3.32x | -3.36x | -4.75x | -5.05x | -5.26x |
| PBR | - | - | - | - | 4.16x | 3.89x | - |
| PEG | - | - | - | 0.2x | -1.4x | 0.84x | 1.29x |
| Capitalization / Revenue | - | - | - | - | - | - | 30x |
| EV / Revenue | - | - | - | - | - | - | -2.52x |
| EV / EBITDA | - | - | - | -3.38x | -3.04x | -2.1x | 0.51x |
| EV / EBIT | -1.08x | -3.23x | -2.4x | -3.37x | -2.01x | -1.3x | 0.3x |
| EV / FCF | - | - | -2.67x | - | -1.99x | -1.41x | 0.27x |
| FCF Yield | - | - | -37.5% | - | -50.2% | -70.8% | 365% |
| Dividend per Share 3 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 3 | - | - | -3 | -2.354 | -2.434 | -2.288 | -2.194 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 5.66 |
| EBITDA 1 | - | - | - | -26.46 | -25 | -27.75 | -28 |
| EBIT 1 | -6.268 | -11.38 | -19.45 | -26.46 | -37.75 | -44.88 | -47.44 |
| Net income 1 | -8.368 | -11.69 | -19.65 | -24.87 | -46.27 | -57.06 | -67.62 |
| Net Debt 1 | - | - | -48.97 | - | -93.65 | -111.4 | -183.8 |
| Reference price 3 | 2.64 | 5.16 | 9.96 | 7.92 | 11.55 | 11.55 | 11.55 |
| Nbr of stocks (in thousands) | 3,483 | 9,399 | 13,818 | 15,459 | 20,831 | - | - |
| Announcement Date | 3/30/23 | 3/27/24 | 3/26/25 | 3/27/26 | - | - | - |
1CAD in Million2USD in Million3CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.75x | - | -3.04x | - | 170M | |
| 35.02x | 8.81x | 27.34x | 0.05% | 57.72B | |
| 19.79x | 6.09x | 13.27x | 1.53% | 52.65B | |
| -42.68x | 14.17x | -41.28x | -.--% | 24.46B | |
| -18.74x | 4.62x | -8.07x | -.--% | 23.84B | |
| 24.1x | 4.75x | 12.43x | -.--% | 19.28B | |
| 24.43x | 4.87x | 15.9x | -.--% | 17.8B | |
| 51.77x | 21.11x | 56.65x | 0.05% | 17.29B | |
| -536.63x | 36.92x | -4116.16x | -.--% | 15.28B | |
| 17.96x | 5.22x | 12.19x | -.--% | 14.35B | |
| Average | -42.97x | 11.84x | -403.08x | 0.18% | 24.28B | |
| Weighted average by Cap. | -18.85x | 10.17x | -247.72x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MSCL Stock
- Valuation Satellos Bioscience Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
